Repligen Corp. (RGEN) Trading 3.9% Higher
Repligen Corp. (NASDAQ:RGEN) shares traded up 3.9% during mid-day trading on Monday . The company traded as high as $29.79 and last traded at $29.72, with a volume of 160,001 shares changing hands. The stock had previously closed at $28.60.
A number of research analysts have recently issued reports on the company. Zacks Investment Research raised Repligen Corp. from a “sell” rating to a “hold” rating in a report on Wednesday, April 6th. Jefferies Group reaffirmed a “hold” rating and set a $28.00 price target on shares of Repligen Corp. in a report on Monday, June 13th.
The firm’s 50-day moving average price is $26.10 and its 200-day moving average price is $25.47. The stock has a market cap of $999.05 million and a P/E ratio of 123.75.
Repligen Corp. (NASDAQ:RGEN) last issued its earnings results on Thursday, May 5th. The company reported $0.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.10 by $0.02. During the same period last year, the firm earned $0.12 earnings per share. The firm had revenue of $25.10 million for the quarter, compared to the consensus estimate of $22.54 million. The company’s revenue for the quarter was up 20.5% on a year-over-year basis. On average, analysts forecast that Repligen Corp. will post $0.47 EPS for the current year.
In other news, VP Howard Benjamin sold 2,889 shares of Repligen Corp. stock in a transaction on Wednesday, May 11th. The stock was sold at an average price of $26.72, for a total value of $77,194.08. Following the transaction, the vice president now directly owns 18,626 shares in the company, valued at approximately $497,686.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Thomas F. Ryan, Jr. sold 5,000 shares of Repligen Corp. stock in a transaction on Thursday, June 30th. The shares were sold at an average price of $26.60, for a total value of $133,000.00. Following the completion of the transaction, the director now owns 12,094 shares in the company, valued at $321,700.40. The disclosure for this sale can be found here.
Several hedge funds and institutional investors recently made changes to their positions in RGEN. Principal Financial Group Inc. increased its position in shares of Repligen Corp. by 4.7% in the fourth quarter. Principal Financial Group Inc. now owns 216,985 shares of the company’s stock worth $6,139,000 after buying an additional 9,758 shares in the last quarter. Globeflex Capital L P increased its position in shares of Repligen Corp. by 50.6% in the fourth quarter. Globeflex Capital L P now owns 36,153 shares of the company’s stock worth $1,023,000 after buying an additional 12,153 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its position in shares of Repligen Corp. by 157.2% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 102,105 shares of the company’s stock worth $2,888,000 after buying an additional 62,405 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Repligen Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 60,884 shares of the company’s stock worth $1,722,000 after buying an additional 984 shares in the last quarter. Finally, Russell Frank Co increased its position in shares of Repligen Corp. by 12.7% in the fourth quarter. Russell Frank Co now owns 66,506 shares of the company’s stock worth $1,933,000 after buying an additional 7,498 shares in the last quarter.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.